Amgen said on Monday its experimental therapy helped patients with advanced gastric cancer live longer when combined with ...

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The FDA said risks linked to CAR-T cell therapies can be effectively communicated through existing labeling, including boxed ...

Despite recent ASCO and FDA guidance recommending the inclusion of people living with HIV in pivotal cancer trials, nearly 75 ...

Pfizer insists that the discontinuation of the Phase II study was due to recruitment difficulties and was not linked to ...

After several years of development, Processa Pharmaceuticals has determined that the nearest milestone for anticancer asset ...

A new medication found to reduce the chance of the most common types of breast cancer recurring will be available to many ...

Restricted availability under an FDA-mandated drug safety program has limited the reach of CAR-T cell therapies for certain ...

A new cancer drug candidate has demonstrated the ability to block tumor growth without triggering a common and debilitating ...

BerGenBio, reeling from the failure of its lead cancer drug, has opted to merge with fellow Norwegian cancer biotech Oncoinvent.